Aug. 21, 2015
Around the globe, cervical cancer is a potentially preventable and curable cancer when detected early. However, cervical cancer still claims many lives among young women living in low and middle income countries (LMICs). In 2008, it was estimated that 529,512 women were diagnosed with cervical cancer and about 274,967 women died of the disease, with the majority being in low-resource countries. Cervical cancer screening can greatly improve these numbers, but implementation of an organized, population-based, cervical cancer screening program has not been done in LMICs due to limited resources, scarcities in trained personnel, and the availability of the appropriate screening test. Two methods of detection have been developed to improve screening, such as visual inspection with acetic acid and high-risk human papilloma virus DNA test. The first screen is limited in that cervical cell aceto-whitening is not specific, and the second is limited because one positive HPV test does not justify medical intervention, but identifies women who have an elevated risk. There is a need for an easy, efficient test that accurately diagnoses a patient with cervical cancer without overdiagnosis leading to overtreatment.
To help improve cervical cancer screening in LMICs, researchers at Purdue University have developed a simple point-of-care colorimetric test, CERVBIO, for onsite cervical cancer screening and treatment. It is a single-use, user-friendly technology utilizing key protein biomarkers that are sensitive and specific to cervical precancerous lesions. From a previous lateral flow immunochromatography design and employing the use of gold nanoparticles with an enzyme (horseradish peroxidase) as a tracer, this is a highly enhanced, multiplex detection of cancer protein markers within 15 to 30 minutes. It enhances the signal by increasing the number of enzyme molecules around the detection site. In addition, further improvement in the limit of detection can be achieved by increasing the interaction time between the target of interest (cervical cancer antigens) and the antibodies. This innovation is advantageous in that it can detect at picogram levels, is colorimetry-based, easy to use (no need for highly trained personnel), rapid, highly sensitive, quantitative, highly affordable, and can be used independently or integrated into existing platforms, making this beneficial for use in LMICs for the screening of cervical cancer.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
justify medical intervention
middle income countries
cervical cell aceto-whitening
cervical precancerous lesions
positive hpv test
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium